908 Devices Inc. (MASS)

In October 2025, the stock advanced following a purchase order from the U.S. Marine Corps and the U.S. Coast Guard. In August 2025, the company reported total revenue of $13.0 million, a 14% year-over-year increase, with recurring revenue growing 28% year-over-year. In May 2025, 908 Devices reported Q1 2025 revenue of $11.8 million, a 59% increase year-over-year, driven by an 86% increase in handheld product and service revenue. In April 2025, the company received a $2 million order from the Texas Department of Public Safety. In March 2025, the stock surged after the company announced a $70 million sale of its desktop portfolio.

908 Devices, Inc. acknowledges the possibility of seasonality in demand for its products, with fluctuations in the mix between device and consumable sales occurring from period to period. The industries it serves, such as life sciences research, bioprocessing, and defense technology, can experience varying demand cycles.

908 Devices, Inc. is a technology company specializing in handheld and desktop mass spectrometry devices for chemical and biochemical analysis, operating in the healthcare and defense technology sectors. Its products include the MX908, a handheld Mass Spec device; XplorIR, a gas identification device; and several bioprocess analyzers. In April 2024, the company acquired RedWave Technology, adding FTIR spectroscopic analyzers to its portfolio. In March 2025, 908 Devices divested its desktop bioprocessing portfolio to Repligen Corporation for $70 million, focusing on its handheld device business and advanced chemical detection.

908 Devices generates most of its revenue from the United States, but also has a presence in Europe, the Middle East, Africa, the Asia Pacific, and the rest of the Americas. Its XplorIR devices are used at military installations both within the United States and overseas, and the U.S. Coast Guard utilizes MX908 devices across the maritime environment.

908 Devices has generally maintained a positive brand reputation, with analysts issuing a "Moderate Buy" consensus rating. The CEO's stock purchases indicate confidence in the company's future, which is further bolstered by the acquisition of RedWave Technology. However, the company faced a goodwill impairment charge of $30,523,000 in November 2024. Broader market challenges include a potential slowdown in cell and gene therapy spending, delays in reimbursement for Exosome tests, tightened research budgets in academic institutions, and currency fluctuations from international operations.

Institutional ownership of 908 Devices, Inc. is substantial, standing at 83.39%, while insider ownership is reported at 8.37%. Rhumbline Advisers increased its stake by 5.5% during the second quarter of 2025, and Bank of New York Mellon Corp grew its stake by 4.0% during the first quarter of 2025.